Actinogen Medical - Further positive XanaCIDD results on depression
New data were revealed from Actinogen Medical’s ongoing analysis of the now-completed XanaCIDD study that support the view that the company’s lead...
314 Views
Actinogen Medical - XanaCIDD data narrow the focus in depression
While the results from Actinogen’s XanaCIDD exploratory Phase IIa study in patients with major depressive disorder (MDD) did not meet the primary...
417 Views
Actinogen Medical - Publication of XanADu biomarker analysis
Actinogen Medical announced that the prespecified biomarker subset analyses on stored plasma samples (n=72) from its previous Phase IIa XanADu...
554 Views
Actinogen Medical - Funding in place through key catalysts
Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering...
347 Views
Actinogen Medical - First patient dosed in Phase IIb XanaMIA study
Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first...
327 Views